No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
MIST250117P5000
- 0.00
- 0.000.00%
15min DelayClose Jan 17 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest5.00Strike Price0.00Turnover0.00%IV-152.53%PremiumJan 17, 2025Expiry Date3.02Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.65Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Express News | Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook Is Bright
Piper Sandler Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $5
Milestone Pharmaceuticals (MIST) Gets a Buy From Piper Sandler
Strategic Positioning and Financial Outlook: Ritu Baral's Buy Rating on Milestone Pharmaceuticals Amidst Etripamil's Promising Market Launch